Evaluating the Impact of Mayo for Diagnostics Companies

24 Apr 2012 10:00 a.m. - 11:00 a.m. PDT

Caitlin Baker
(202) 887-8755

Click here to access the recorded webcast.

The Supreme Court's decision in Mayo Collaborative Services v. Prometheus Labs, issued on March 20, 2012, has left the entire diagnostics industry wondering what to do with their patent portfolios now and going forward. The guiding principle from Mayo will be that an observed correlation or relationship is not itself patentable because it constitutes a "law of nature," which is excluded from patent protection. However, while the Court did advise that a claimed process should do more than simply instruct users to apply the natural law, it was vague on what exactly constitutes a patent eligible application of a natural law.

In this one-hour Webinar, experienced counsel, including patent prosecution and litigation experts, will discuss the implications for the diagnostics industry, including:

  • An industry perspective on the impact of Mayo on the diagnostics industry as a whole
  • Practical insight into adjusting ones existing prosecution and litigation strategies in light of Mayo
  • Solutions for developing and implementing new strategies going forward


  • Matthew Kreeger, Partner, Morrison & Foerster LLP
  • Otis Littlefield, Partner, Morrison & Foerster LLP
  • Ken Goldman, Global Head, Diagnostic Patents, Novartis Pharma Services AG




Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.